Genenta Science Ownership
| GNTA Stock | USD 4.37 0.55 14.40% |
Genenta |
Genenta Stock Ownership Analysis
About 39.0% of the company shares are held by company insiders. The book value of Genenta Science was currently reported as 0.92. The company recorded a loss per share of 0.51. Genenta Science SpA had not issued any dividends in recent years. Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company was incorporated in 2014 and is headquartered in Milan, Italy. Genenta Science is traded on NASDAQ Exchange in the United States. To learn more about Genenta Science SpA call the company at 39 02 26 43 46 81 or check out https://www.genenta.com.Besides selling stocks to institutional investors, Genenta Science also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Genenta Science's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Genenta Science's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Genenta Science Quarterly Liabilities And Stockholders Equity |
|
About 39.0% of Genenta Science SpA are currently held by insiders. Unlike Genenta Science's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Genenta Science's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Genenta Science's insider trades
Genenta Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Genenta Science is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genenta Science SpA backward and forwards among themselves. Genenta Science's institutional investor refers to the entity that pools money to purchase Genenta Science's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alti Global Inc | 2024-09-30 | 200.3 K | Algebris Investment Management (uk) Llp | 2024-12-31 | 45 K | Ubs Group Ag | 2024-09-30 | 1.9 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 500 |
Genenta Science SpA Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Genenta Science insiders, such as employees or executives, is commonly permitted as long as it does not rely on Genenta Science's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Genenta Science insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rosenwald Lindsay A Md over a month ago Disposition of 506245 shares by Rosenwald Lindsay A Md of Genenta Science subject to Rule 16b-3 | ||
Driscoll Martin J over two months ago Acquisition by Driscoll Martin J of 4999 shares of Genenta Science at 0.25 subject to Rule 16b-3 | ||
Rosenwald Lindsay A Md over six months ago Disposition of 64562 shares by Rosenwald Lindsay A Md of Genenta Science subject to Rule 16b-3 | ||
Rosenwald Lindsay A Md over six months ago Disposition of 2287 shares by Rosenwald Lindsay A Md of Genenta Science subject to Rule 16b-3 |
Genenta Science Outstanding Bonds
Genenta Science issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Genenta Science SpA uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Genenta bonds can be classified according to their maturity, which is the date when Genenta Science SpA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Genenta Science Corporate Filings
| 10th of February 2025 Other Reports | ViewVerify | |
6K | 30th of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 20th of December 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genenta Science SpA offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genenta Science's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genenta Science Spa Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genenta Science Spa Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genenta Science SpA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genenta Science. If investors know Genenta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genenta Science listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Genenta Science SpA is measured differently than its book value, which is the value of Genenta that is recorded on the company's balance sheet. Investors also form their own opinion of Genenta Science's value that differs from its market value or its book value, called intrinsic value, which is Genenta Science's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genenta Science's market value can be influenced by many factors that don't directly affect Genenta Science's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genenta Science's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genenta Science is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genenta Science's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.